Novartis AG Return on Investment 1996-2025 | NVS

Current and historical return on investment (ROI) values for Novartis AG (NVS) over the last 10 years.
Novartis AG ROI - Return on Investment Historical Data
Date TTM Net Income LT Investments & Debt Return on Investment
2025-06-30 $16.68B $64.52B 25.93%
2025-03-31 $15.83B $60.12B 24.90%
2024-12-31 $14.54B $65.49B 23.16%
2024-09-30 $13.60B $67.19B 21.68%
2024-06-30 $11.73B $61.57B 19.55%
2024-03-31 $10.52B $56.95B 16.93%
2023-12-31 $9.77B $65.19B 14.79%
2023-09-30 $8.23B $56.31B 11.81%
2023-06-30 $8.29B $70.19B 10.94%
2023-03-31 $7.71B $72.54B 9.70%
2022-12-31 $7.95B $79.67B 9.63%
2022-09-30 $9.47B $80.63B 11.10%
2022-06-30 $10.88B $85.24B 12.78%
2022-03-31 $12.13B $84.50B 14.51%
2021-12-31 $11.69B $90.72B 14.34%
2021-09-30 $15.52B $80.04B 19.51%
2021-06-30 $10.95B $78.96B 13.72%
2021-03-31 $9.82B $76.34B 12.35%
2020-12-31 $10.15B $82.93B 12.83%
2020-09-30 $5.58B $81.05B 7.21%
2020-06-30 $9.28B $77.84B 12.32%
2020-03-31 $9.59B $74.78B 12.99%
2019-12-31 $9.09B $75.90B 12.57%
2019-09-30 $8.63B $72.73B 10.98%
2019-06-30 $8.51B $71.87B 9.94%
2019-03-31 $8.27B $68.53B 8.95%
2018-12-31 $8.40B $101.16B 8.49%
2018-09-30 $9.11B $100.62B 9.29%
2018-06-30 $9.23B $99.66B 9.54%
2018-03-31 $9.08B $94.41B 9.55%
2017-12-31 $8.63B $97.45B 9.17%
2017-09-30 $8.01B $95.53B 11.49%
2017-06-30 $7.93B $92.98B 11.45%
2017-03-31 $7.74B $90.58B 11.35%
2016-12-31 $8.27B 12.23%
2016-09-30 $8.49B $93.33B 9.33%
2016-06-30 $8.46B $88.81B 9.37%
2016-03-31 $8.64B $88.35B 9.49%
2015-12-31 $8.98B $93.45B 9.78%
2015-09-30 $9.65B $90.20B 10.78%
2015-06-30 $10.16B $92.13B 11.54%
2015-03-31 $11.06B $91.28B 12.88%
2014-12-31 $11.09B $84.64B 13.14%
2014-09-30 $11.23B $84.09B 13.27%
2014-06-30 $11.05B $83.39B 13.08%
2014-03-31 $10.90B $85.54B 12.99%
2013-12-31 $10.98B $85.71B 13.35%
2013-09-30 $11.20B $83.30B 13.73%
2013-06-30 $11.59B $81.24B 14.22%
2013-03-31 $11.67B $78.76B 14.46%
2012-12-31 $11.51B $83.04B 14.33%
2012-09-30 $9.89B $83.03B 12.44%
2012-06-30 $9.89B $78.00B 12.57%
2012-03-31 $10.11B $77.10B 12.72%
2011-12-31 $10.78B $79.80B 13.45%
2011-09-30 $12.15B $79.88B 14.96%
2011-06-30 $11.78B $81.02B 14.48%
2011-03-31 $11.42B $79.87B 14.57%
2010-12-31 $11.53B $84.13B 15.25%
2010-09-30 $11.70B $80.55B 16.45%
2010-06-30 $11.74B $69.05B 17.67%
2010-03-31 $11.15B $68.66B 17.38%
2009-12-31 $9.98B $66.14B 16.56%
2009-09-30 $9.03B $62.02B 15.87%
2009-06-30 $8.73B $59.68B 15.99%
2009-03-31 $8.82B $53.21B 16.62%
2008-12-31 $8.96B $52.62B 17.14%
2008-09-30 $8.18B $52.80B 15.83%
2008-06-30 $7.30B $53.78B 14.31%
2008-03-31 $6.93B $50.01B 14.26%
2007-12-31 $6.78B $50.07B 14.61%
2007-09-30 $7.53B $50.16B 16.95%
2007-06-30 $8.05B $44.30B 19.18%
2007-03-31 $7.92B $41.16B 19.50%
2006-12-31 $7.64B $41.95B 19.55%
2006-09-30 $7.09B $40.55B 19.05%
2006-06-30 $7.00B $38.78B 19.64%
2006-03-31 $6.89B $35.10B 20.15%
2005-12-31 $6.51B $34.48B 19.48%
2005-09-30 $6.79B $34.18B 20.40%
2005-06-30 $6.51B $32.90B 19.89%
2005-03-31 $6.36B $32.06B 19.66%
2004-12-31 $6.12B $34.05B 19.09%
2004-09-30 $6.09B $31.83B 19.06%
2004-06-30 $5.96B $31.40B 18.69%
2004-03-31 $5.72B $30.91B 18.21%
2003-12-31 $5.64B $33.71B 17.93%
2003-09-30 $3.89B $31.58B 12.65%
2003-06-30 $3.74B $29.50B 12.61%
2003-03-31 $3.61B $30.91B 12.18%
2002-12-31 $3.35B $31.06B 11.76%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $218.425B $50.545B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $495.141B 66.87
Johnson & Johnson (JNJ) United States $450.090B 16.68
Novo Nordisk (NVO) Denmark $424.453B 49.78
Merck (MRK) United States $270.018B 37.87
AbbVie (ABBV) United States $264.086B 11.85
AstraZeneca (AZN) United Kingdom $218.471B 19.74
Pfizer (PFE) United States $201.199B 7.39
Sanofi (SNY) $132.955B 11.89
Innoviva (INVA) United States $0.953B 10.12